‘Obviously ChatGPT’ — how reviewers accused me of scientific fraud
By E.M. Wolkovich,
Nature
| 02. 05. 2024
I have just been accused of scientific fraud. Not data fraud — no one accused me of fabricating or misleadingly manipulating data or results. This, I suppose, is a relief because my laboratory, which studies how global change reshapes ecological communities, works hard to ensure that data are transparent and sharable, and that our work is reproducible. Instead, I was accused of writing fraud: passing off ‘writing’ produced by artificial intelligence (AI) as my own. That hurts, because — like many people — I find writing a paper to be a somewhat painful process. I read books on how to write — both to be comforted by how much these books stress that writing is generally slow and difficult, and to find ways to improve. My current strategy involves willing myself to write and creating several outlines before the first draft, which is followed by writing and a lot of revising. I always suggest this approach to my students, although I know it is not easy, because I think it’s important that scientists try to communicate well.
Imagine my surprise...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...